Last reviewed · How we verify

Azienda Ospedaliero-Universitaria di Parma — Portfolio Competitive Intelligence Brief

Azienda Ospedaliero-Universitaria di Parma pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Metformin-Sitagliptin-Empaglifozin-Pioglitazone Metformin-Sitagliptin-Empaglifozin-Pioglitazone phase 3 Oral antidiabetic combination (metformin + DPP-4 inhibitor + SGLT2 inhibitor + thiazolidinedione) Multiple: AMPK/mitochondrial (metformin), DPP-4 (sitagliptin), SGLT2 (empaglifozin), PPAR-γ (pioglitazone) Diabetes

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Azienda Ospedaliero-Universitaria di Parma:

Cite this brief

Drug Landscape (2026). Azienda Ospedaliero-Universitaria di Parma — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/azienda-ospedaliero-universitaria-di-parma. Accessed 2026-05-17.

Related